192 related articles for article (PubMed ID: 33102814)
1. Cucurbitacin E and I target the JAK/STAT pathway and induce apoptosis in Sézary cells.
Brouwer IJ; Out-Luiting JJ; Vermeer MH; Tensen CP
Biochem Biophys Rep; 2020 Dec; 24():100832. PubMed ID: 33102814
[TBL] [Abstract][Full Text] [Related]
2. Cucurbitacin I inhibits Stat3 and induces apoptosis in Sézary cells.
van Kester MS; Out-Luiting JJ; von dem Borne PA; Willemze R; Tensen CP; Vermeer MH
J Invest Dermatol; 2008 Jul; 128(7):1691-5. PubMed ID: 18200050
[TBL] [Abstract][Full Text] [Related]
3. Activation of Jak/STAT proteins involved in signal transduction pathway mediated by receptor for interleukin 2 in malignant T lymphocytes derived from cutaneous anaplastic large T-cell lymphoma and Sezary syndrome.
Zhang Q; Nowak I; Vonderheid EC; Rook AH; Kadin ME; Nowell PC; Shaw LM; Wasik MA
Proc Natl Acad Sci U S A; 1996 Aug; 93(17):9148-53. PubMed ID: 8799169
[TBL] [Abstract][Full Text] [Related]
4. Cucurbitacin Q: a selective STAT3 activation inhibitor with potent antitumor activity.
Sun J; Blaskovich MA; Jove R; Livingston SK; Coppola D; Sebti SM
Oncogene; 2005 May; 24(20):3236-45. PubMed ID: 15735720
[TBL] [Abstract][Full Text] [Related]
5. Cucurbitacin-I inhibits Aurora kinase A, Aurora kinase B and survivin, induces defects in cell cycle progression and promotes ABT-737-induced cell death in a caspase-independent manner in malignant human glioma cells.
Premkumar DR; Jane EP; Pollack IF
Cancer Biol Ther; 2015; 16(2):233-43. PubMed ID: 25482928
[TBL] [Abstract][Full Text] [Related]
6. Deregulation in STAT signaling is important for cutaneous T-cell lymphoma (CTCL) pathogenesis and cancer progression.
Netchiporouk E; Litvinov IV; Moreau L; Gilbert M; Sasseville D; Duvic M
Cell Cycle; 2014; 13(21):3331-5. PubMed ID: 25485578
[TBL] [Abstract][Full Text] [Related]
7. The cross-talk between miRNAs and JAK/STAT pathway in cutaneous T cell lymphoma: Emphasis on therapeutic opportunities.
Patil K; Sher G; Kuttikrishnan S; Moton S; Alam M; Buddenkotte J; Ahmad A; Steinhoff M; Uddin S
Semin Cell Dev Biol; 2024 Feb; 154(Pt C):239-249. PubMed ID: 36216715
[TBL] [Abstract][Full Text] [Related]
8. ECPIRM, a Potential Therapeutic Agent for Cutaneous T-Cell Lymphoma, Inhibits Cell Proliferation and Promotes Apoptosis via a JAK/STAT Pathway.
Yang H; Ma P; Cao Y; Zhang M; Li L; Wei J; Tao L; Qian K
Anticancer Agents Med Chem; 2018; 18(3):401-411. PubMed ID: 28356009
[TBL] [Abstract][Full Text] [Related]
9. Avicin D selectively induces apoptosis and downregulates p-STAT-3, bcl-2, and survivin in cutaneous T-cell lymphoma cells.
Zhang C; Li B; Gaikwad AS; Haridas V; Xu Z; Gutterman JU; Duvic M
J Invest Dermatol; 2008 Nov; 128(11):2728-2735. PubMed ID: 18496567
[TBL] [Abstract][Full Text] [Related]
10. Cucurbitacin: ancient compound shedding new light on cancer treatment.
Lee DH; Iwanski GB; Thoennissen NH
ScientificWorldJournal; 2010 Mar; 10():413-8. PubMed ID: 20209387
[TBL] [Abstract][Full Text] [Related]
11. Potential of cucurbitacin as an anticancer drug.
Li Y; Li Y; Yao Y; Li H; Gao C; Sun C; Zhuang J
Biomed Pharmacother; 2023 Dec; 168():115707. PubMed ID: 37862969
[TBL] [Abstract][Full Text] [Related]
12. Ruxolitinib with resminostat exert synergistic antitumor effects in Cutaneous T-cell Lymphoma.
Karagianni F; Piperi C; Mpakou V; Spathis A; Foukas PG; Dalamaga M; Pappa V; Papadavid E
PLoS One; 2021; 16(3):e0248298. PubMed ID: 33705488
[TBL] [Abstract][Full Text] [Related]
13. Potent Anticancer Effects of Epidithiodiketopiperazine NT1721 in Cutaneous T Cell Lymphoma.
Lin M; Kowolik CM; Xie J; Yadav S; Overman LE; Horne DA
Cancers (Basel); 2021 Jul; 13(13):. PubMed ID: 34282785
[TBL] [Abstract][Full Text] [Related]
14. JAK3 Is Expressed in the Nucleus of Malignant T Cells in Cutaneous T Cell Lymphoma (CTCL).
Vadivel CK; Gluud M; Torres-Rusillo S; Boding L; Willerslev-Olsen A; Buus TB; Nielsen TK; Persson JL; Bonefeld CM; Geisler C; Krejsgaard T; Fuglsang AT; Odum N; Woetmann A
Cancers (Basel); 2021 Jan; 13(2):. PubMed ID: 33466582
[TBL] [Abstract][Full Text] [Related]
15. Cucurbitacin B inhibits cell proliferation and induces apoptosis in human osteosarcoma cells via modulation of the JAK2/STAT3 and MAPK pathways.
Zhang ZR; Gao MX; Yang K
Exp Ther Med; 2017 Jul; 14(1):805-812. PubMed ID: 28673003
[TBL] [Abstract][Full Text] [Related]
16. An overview of cutaneous T cell lymphomas.
Bagherani N; Smoller BR
F1000Res; 2016; 5():. PubMed ID: 27540476
[TBL] [Abstract][Full Text] [Related]
17. STAT3 knockdown by siRNA induces apoptosis in human cutaneous T-cell lymphoma line Hut78 via downregulation of Bcl-xL.
Verma NK; Davies AM; Long A; Kelleher D; Volkov Y
Cell Mol Biol Lett; 2010 Jun; 15(2):342-55. PubMed ID: 20213502
[TBL] [Abstract][Full Text] [Related]
18. Apoptotic and antimetastatic effect of cucurbitacins in cancer: recent trends and advancement.
Kumar A; Sharma B; Sharma U; Parashar G; Parashar NC; Rani I; Ramniwas S; Kaur S; Haque S; Tuli HS
Naunyn Schmiedebergs Arch Pharmacol; 2023 Sep; 396(9):1867-1878. PubMed ID: 37010571
[TBL] [Abstract][Full Text] [Related]
19. JAK inhibition synergistically potentiates BCL2, BET, HDAC, and proteasome inhibition in advanced CTCL.
Yumeen S; Mirza FN; Lewis JM; King ALO; Kim SR; Carlson KR; Umlauf SR; Surovtseva YV; Foss FM; Girardi M
Blood Adv; 2020 May; 4(10):2213-2226. PubMed ID: 32437546
[TBL] [Abstract][Full Text] [Related]
20. The antihistamines clemastine and desloratadine inhibit STAT3 and c-Myc activities and induce apoptosis in cutaneous T-cell lymphoma cell lines.
Döbbeling U; Waeckerle-Men Y; Zabel F; Graf N; Kündig TM; Johansen P
Exp Dermatol; 2013 Feb; 22(2):119-24. PubMed ID: 23362870
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
